Sam-A Pharm. Co., Ltd (KOSDAQ:009300)
13,970
+280 (2.05%)
At close: Aug 24, 2026
Sam-A Pharm. Revenue
Sam-A Pharm. had revenue of 18.78B KRW in the quarter ending June 30, 2026, with 7.79% growth. This brings the company's revenue in the last twelve months to 72.28B, down -12.40% year-over-year. In the year 2025, Sam-A Pharm. had annual revenue of 77.80B, down -18.60%.
Revenue (ttm)
72.28B
Revenue Growth
-12.40%
P/S Ratio
1.16
Revenue / Employee
237.00M
Employees
305
Market Cap
83.55B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 77.80B | -17.78B | -18.60% |
| Dec 31, 2024 | 95.58B | -1.63B | -1.68% |
| Dec 31, 2023 | 97.21B | 15.51B | 18.99% |
| Dec 31, 2022 | 81.70B | 27.03B | 49.45% |
| Dec 31, 2021 | 54.67B | 1.01B | 1.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| H.PIO | 266.01B |
| DongKoo Bio & Pharma | 241.43B |
| Daehan Nupharm | 205.39B |
| Sinsin Pharmaceutical | 118.65B |
| Hwail Pharmaceutical | 107.87B |
| KOREA PHARMA | 93.94B |
| OPTUS Pharmaceutical | 91.62B |
| Sinil Pharmaceutical | 82.18B |